Latest News

Australia’s premier life sciences investment forum opened in Melbourne earlier this week, bringing together investors, innovators and global partners to explore one of the most dynamic periods in the nation’s biotechnology and medical technology sectors.

Telix Pharmaceuticals (ASX:TLX) has dosed the first patient in its Phase 1 clinical trial evaluating TLX090 (¹⁵³Samarium (Sm)-DOTMP), a next-generation therapeutic radiopharmaceutical being developed to treat pain associated with metastatic bone disease.

Moderna has announced that Michael Azrak, General Manager for Australia and New Zealand, will leave the company in January 2026 to take up a new opportunity.

Arty Miritis joins Gilead with more than two decades of leadership and commercial experience across the pharmaceutical sector, having held senior roles in Australia, New Zealand and international markets.

The therapy has been added to the Life Saving Drugs Program more than two years after the Pharmaceutical Benefits Advisory Committee rejected it for reimbursement via the PBS.

Fast-growing sales of GLP-1 medicines have boosted Chemist Warehouse, with the network reporting a 17.9 per cent increase in sales for the three months to the end of September compared to the corresponding period last year.

The challenge in comparing pharmaceutical pricing systems lies in their structural differences. The US model is built on multiple layers of rebates, discounts and incentives, while single-payer systems rely on centralised negotiations and confidential agreements.

Contract pharmaceutical manufacturer IDT Australia has announced a strategic realignment to sharpen its operational focus, deliver $1 million in annualised cost savings from the financial year 2026, and position the business for more sustainable growth.

This creates a catch-all mechanism for non-disclosure. It could mean that critical information, the kind that has historically exposed poor behaviour, governance or forced policy change, such as PBS-related decisions, the games behind the 'Vancouver' poster or ODTP program reforms, may never see the light of day.

Dr Naseem Ali, Medical Affairs Lead for Astellas Australia, said, 'This is especially important as Australia recorded over 26,000 men diagnosed with prostate cancer last year, and we know some of whom will be at high-risk of experiencing BCR."

The Services Australia Annual Report 2024–25 has revealed a sharp rise in activity under the Pharmaceutical Benefits Scheme, reinforcing its place as one of the country’s most significant and critical public health programs.

A landmark study led by Monash University has revealed a sharp rise in endometriosis diagnoses among women attending Australian general practices over the past decade.